Detalhe da pesquisa
1.
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
Blood
; 139(12): 1850-1862, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34695176
2.
[Board-certified "hematologist" and "clinical laboratory physician": double jobbing-flow with the tide].
Rinsho Ketsueki
; 64(8): 799-802, 2023.
Artigo
em Japonês
| MEDLINE | ID: mdl-37673633
3.
[Treatment strategy for acute lymphoblastic leukemia in adolescent and young adults].
Rinsho Ketsueki
; 63(7): 826-832, 2022.
Artigo
em Japonês
| MEDLINE | ID: mdl-35922954
4.
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study.
Am J Hematol
; 95(3): 251-257, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31804748
5.
Differences in Diagnostic Properties Between Standard and Enrichment Culture Techniques Used in Periprosthetic Joint Infections.
J Arthroplasty
; 35(1): 235-240, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31522855
6.
Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).
Hematol Oncol
; 36(1): 202-209, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28681529
7.
Diagnostics for multiple myeloma.
Rinsho Ketsueki
; 57(10): 2096-2103, 2016.
Artigo
em Japonês
| MEDLINE | ID: mdl-27795519
8.
[Successful induction therapy for acute myeloid leukemia complicated with brain hemorrhage and hyperleukocytosis].
Rinsho Ketsueki
; 57(2): 180-5, 2016 Feb.
Artigo
em Japonês
| MEDLINE | ID: mdl-26935637
9.
Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.
Hematol Oncol
; 33(1): 9-14, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24519501
10.
[Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy].
Rinsho Ketsueki
; 56(4): 392-9, 2015 Apr.
Artigo
em Japonês
| MEDLINE | ID: mdl-25971269
11.
European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.
Cancer Sci
; 105(1): 105-9, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450386
12.
Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
Eur J Haematol
; 92(3): 204-10, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24283206
13.
Impact of steroid medication before hospital admission on barotrauma in mechanically ventilated patients with acute respiratory distress syndrome in intensive care units.
J Anesth
; 28(5): 681-6, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24554247
14.
[T315I positive promyelocytic crisis of chronic myeloid leukemia].
Rinsho Ketsueki
; 55(6): 692-6, 2014 Jun.
Artigo
em Japonês
| MEDLINE | ID: mdl-24975339
15.
R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.
Br J Haematol
; 161(3): 383-8, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23432318
16.
Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome.
Int J Hematol
; 118(4): 494-502, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37062784
17.
SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.
Cancer Sci
; 103(8): 1518-23, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22587388
18.
[Immune-mediated encephalomyelitis following varicella-zoster virus infection after allogeneic stem cell transplantation].
Rinsho Ketsueki
; 53(4): 465-8, 2012 Apr.
Artigo
em Japonês
| MEDLINE | ID: mdl-22687982
19.
[Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].
Rinsho Ketsueki
; 53(7): 698-704, 2012 Jul.
Artigo
em Japonês
| MEDLINE | ID: mdl-22975772
20.
Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
Vaccine
; 40(19): 2652-2655, 2022 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35370020